Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. …

After Eli Lilly granted an apparently well-connected 79-year-old patient special access to retatrutide, an unapproved obesity drug, the company confirmed that it will allow other patients to apply for early access, STAT tells us. The move comes six weeks after STAT reported the expanded access and followed up this week about further requests from a handful of doctors who had not yet received a reply from the drugmaker. It marks a striking change in the public posture of the company, which had previously offered little information about the special access program. The initial patient accessed the drug in April via the U.S. Food and Drug Administration’s “compassionate use” program.

The California Supreme Court sided with Gilead Sciences in a closely watched case brought by thousands of patients who argued the company was negligent for slow-walking development of an HIV medicine that was safer than another drug it was already selling, STAT writes. In a 6-to-1 decision, the court overturned a state appeals court ruling two years ago that Gilead could be held liable, raising alarm in the pharmaceutical industry that drug development decisions could be influenced by the fear of legal liability and dissuade innovation.